Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis

Hepatology

Volumn 51, Issue 1, 2010, Pages 174-180

  Bangarulingam, Sanjay Y ^a   Bjornsson, Einar ^a   Enders, Felicity ^a   Barr Fritcher, Emily G ^a   Gores, Gregory ^a   Halling, Kevin C ^a   Lindor, Keith D ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CA 19-9 ANTIGEN;

ADULT; ARTICLE; BILE DUCT CARCINOMA; BILE DUCT OBSTRUCTION; BILIRUBIN BLOOD LEVEL; CANCER SCREENING; CONTROLLED STUDY; CYTODIAGNOSIS; DIAGNOSTIC VALUE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TETRASOMY; TRISOMY;

ADULT; ANEUPLOIDY; CHOLANGIOCARCINOMA; CHOLANGITIS, SCLEROSING; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIERS ESTIMATE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED;

EID: 73449133724     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.23277     Document Type: Article

References (28)

1. Broome U, Olsson R, Loof L. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996;38:610-615.
2. Khan SA, Davidson BR, Goldin R. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 2002;51(Suppl. 6):VI1-VI9.
3. Helzberg JH, Peterson JM, Boyer JL. Improved survival with primary sclerosing cholangitis: a review of the clinicopathologic features and comparison of symptomatic and asymptomatic patients. Gastroenterology 1987;92:1869-1875.
4. Miros M, Kerlin P, Walker N. Predicting cholangiocarcinoma in patients with primary sclerosing cholangitis before transplantation. Gut 1991;32:1369-1373.
5. Burak K, Angulo P, Pasha TM. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004;99:523-526.
6. Farrant JM, Hayllar KM, Wilkinson ML. Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology 1991;100:1710-1717.
7. Bergquist A, Ekbom A, Olsson R. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002;36:321-327.
8. Bergquist A, Tribukait B, Glaumann H, Broome U. Can DNA cytometry be used for evaluation of malignancy and premalignancy in bile duct strictures in primary sclerosing cholangitis? J Hepatol 2000;33:873-877.
9. Charatcharoenwitthaya P, Felicity E, Halling K, Lindor K. Enders. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. HEPATOLOGY 2008;48:1106-1117.
10. Moreno Luna LE, Kipp B, Halling KC, Sebo TJ, Kremers WK, Roberts LR, et al. Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. Gastroenterology 2006;131:1064-1072.
11. Fritcher EG, Kipp BR, Halling KC, Oberg TN, Bryant SC, Tarrell RF, et al. A multivariable model using advanced cytologic methods for the eval-uation of indeterminate pancreatobiliary strictures. Gastroenterology 2009;136:2180-2186.
12. Halling KC, King W, Sokolova IA, Meyer RG, Burkhardt HM, Halling AC, http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search& Term=%22Cheville%20JC%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed. Pubmed-ResultsPanel.Pubmed-DiscoveryPanel.Pubmed- RVAbstractPlus et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol 2000;164: 1768-1775.
13. Kipp BR, Stadheim LM, Halling SA, Pochron NL, Harmsen S, Nagorney DM, et al. A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures. Am J Gastroenterol 2004;99:1675-1681.
14. Sokolova IA, Halling KC, Jenkins RB, Burkhardt HM, Meyer RG, Seelig SA, et al. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn 2000;2:116-123.
15. Persons DL, Takai K, Gibney DJ, Katzmann JA, Lieber MM, Jenkins RB. Comparison of fluorescence in situ hybridization with flow cytometry and static image analysis in ploidy analysis of paraffin-embedded prostate adenocarcinoma. Hum Pathol 1994;25:678-683.
16. Baron TH, Harewood GC, Rumalla A, Pochron NL, Stadheim LM, Gores GJ, et al. A prospective comparison of digital image analysis and routine cytology for the identification of malignancy in biliary tract strictures. Clin Gastroenterol Hepatol 2004;2:214-219.
17. Barr Fritcher EG, Kipp BR, Slezak JM, Moreno-Luna LE, Gores GJ, Levy MJ, et al. Correlating routine cytology, quantitative nuclear morphometry by digital image analysis, and genetic alterations by fluorescence in situ hybridization to assess the sensitivity of cytology for detecting pancreatobiliary tract malignancy. Am J Clin Pathol 2007;128:272-279.
18. De Bellis M, Sherman S, Fogel EL, Cramer H, Chappo J, McHenry L Jr, et al. Tissue sampling at ERCP in suspected malignant biliary strictures (Part 1). Gastrointest Endosc 2002;56:552-561.
19. Levy MJ, Baron TH, Clayton AC, Enders FB, Gostout CJ, Halling KC, et al. Prospective evaluation of advanced molecular markers and imaging techniques in patients with indeterminate bile duct strictures. Am J Gastroenterol 2008;103:1263-1273.
20. LaRusso NF, Shneider BL, Black D, Gores GJ, James SP, Doo E, et al. Primary sclerosing cholangitis: summary of a workshop. HEPATOLOGY 2006;44:746-764.
21. MacCarty RL, LaRusso NF, Wiesner RH, Ludwig J. Primary sclerosing cholangitis: findings on cholangiography and pancreatography. Radiology 1983;149:39-44.
22. Kipp BR, Sebo TJ, Griffin MD, Ihrke JM, Halling KC. Analysis of polyomavirus-infected renal transplant recipients' urine specimens: correlation of routine urine cytology, fluorescence in situ hybridization, and digital image analysis. Am J Clin Pathol 2005;124:854-861.
23. Kipp BR, Campion MB, Coffman E, Smith A, Tomisek JD, Browne GG, http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search& Term=%22Panella%20JR%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed. Pubmed-ResultsPanel.Pubmed-DiscoveryPanel. Pubmed-RVAbstractPluset al. An evaluation of ThinPrep UroCyte filters for the preparation of slides for fluorescence in situ hybridization. Diagn Cytopathol 2006;34:479-484.
24. Rea DJ, Heimbach JK, Rosen CB, Haddock MG, Alberts SR, Kremers WK, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005;242:451-458.
25. Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. HEPATOLOGY 2008;48:308-321.
26. DeHaan RD, Kipp BR, Smyrk TC, Abraham SC, Roberts LR, Halling KC. An assessment of chromosomal alterations detected by fluorescence in situ hybridization and p16 expression in sporadic and primary sclerosing cholangitis-associated cholangiocarcinomas. Hum Pathol 2007;38:491-499.
27. Brankley SM, Wang KK, Harwood AR, Miller DV, Legator MS, Lutzke LS, et al. The development of a fluorescence in situ hybridization assay for the detection of dysplasia and adenocarcinoma in Barrett's esophagus. J Mol Diagn 2006;8:260-267.
28. Fritcher EG, Brankley SM, Kipp BR, Voss JS, Campion MB, Morrison LE, et al. A comparison of conventional cytology, DNA ploidy analysis, and fluorescence in situ hybridization for the detection of dysplasia and adenocarcinoma in patients with Barrett's esophagus. Hum Pathol 2008;39:1128-1135.